Vol. 17/No. 12 | OncologyLive

Everolimus Survival Benefit Suggested in Updated NET Trial Results

June 23, 2016

Patients with nonfunctioning neuroendocrine tumors of lung or gastrointestinal origin continued to live longer when treated with the mammalian target of rapamycin inhibitor everolimus (Afinitor) than with placebo.

Breast Cancer Milestones Are Unfolding on Several Fronts

June 20, 2016

During the past 2 years, there have been a number of advancements in the treatment of metastatic breast cancer that include the development of novel agents and new strategies in several disease settings, resulting in improved outcomes for patients.

New Criteria and Novel Agents May Help Spur MDS Advances

June 18, 2016

Although knowledge about the underlying biology of myelodysplastic syndromes has expanded rapidly in recent years, translating those findings into advances in the diagnosis and management of patients remains a significant challenge.

Biosimilar Era Gets Rolling in Oncology

June 17, 2016

After years of anticipation, biosimilar versions of the most widely administered monoclonal antibodies in oncology care are moving closer to fruition for the US market, starting with a new form of trastuzumab (Herceptin).

Second-Generation AR-Targeting Agent Explored in High-Risk Prostate Cancer

June 15, 2016

Researchers are hoping the results of a late-stage efficacy and safety study of apalutamide in patients with high-risk, localized, or locally advanced prostate cancer who are receiving primary radiation therapy will demonstrate an improvement in metastasis-free survival.

Study Calls for Basing Lung Cancer Screening Guidelines on Individual Risk

May 26, 2016

An individualized, risk-based approach to screening current and former smokers for the early detection of lung cancer would dramatically expand the population that could benefit from the preventive strategy, while saving more lives than the current US Preventive Services Task Force guidelines for lung cancer screening.